LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
LB Pharmaceuticals has commenced its pivotal Phase 3 NOVA-2 trial to evaluate LB-102, a novel oral benzamide antipsychotic candidate, for the treatment of schizophrenia in approximately 460 U.S. patients. LB-102 showed promising Phase 2 results with significant symptom improvement and a favorable safety profile. Topline data from NOVA-2 are expecte…